Technology Transfer Tactics will be offering an audioconference entitled "The Future of Patenting in Biomedicine" on August 26, 2010 from 1:00 - 2:30 PM (EDT). Patent Docs author Dr. Kevin Noonan of McDonnell Boehnen Hulbert & Berghoff LLP and Professor Chris Holman of the University of Missouri-Kansas City School of Law will take an in-depth look at the effect of the Myriad case on gene patenting and genetic diagnostics and address strategies that universities and innovators can employ to ensure sufficient patent protection and maximize investment opportunities. The speakers will cover the following topics:
"Detect and infer" claims:
• All diagnostic claims have this format, no matter what is being diagnosed -- how should they be analyzed?
• What is the significance of the "detecting" step with regard to novelty?
• Does patent eligibility depend on the nature of what is detected (metabolites? proteins? genes?)
• Should there be a physician exception from infringement (as there is for medical procedure claims)?
• What is the relevance of any "mental steps" involved in the claims?
• Justice Breyer: the impact of merely reading numbers in light of medical knowledge
• Should a medical degree be enough to distinguish (versus an auto mechanic, for example)?
The impact of recent case law:
• Bilski and what it says about medical diagnostic claims
• What can we expect from the Federal Circuit?
• Lessons learned and hints from other recent cases: Classen, Prometheus, Myriad
• The significance of genetic methods as a subset of medical diagnostic claims
• Relationship between information per se and methods of obtaining information
• Consequences of an outright ban: Hiding information as trade secret
• Gene patenting bills in Congress
• Is there a middle ground?
The registration fee for the audioconference is $197 ($247 for registration plus CLE processing). Those interested in registering for the audioconference, can do so here, by calling 877-729-0959 or 239-263-0605, or by faxing or e-mailing this form to 404-381-1354 or email@example.com.